Investors2021-07-21T12:24:50+00:00

Investor Information

Stock Chart

View Listing

Diary Of A Psychedelic Executive

Since we listed Psyence on the Canadian Securities Exchange (CSE) in January 2021, we have commenced cultivation, started research and development, and recruited extraordinary medical and scientific talent to collaborate in finding psychedelic-assisted solutions to the current mental health crisis. The enduring work of Psyence is to develop and provide innovative, safe and responsible psychedelic and nature-based solutions for mental health and mental wellness that heal, open consciousness, and nurture community.

This is a unique time in the history of medicine and pharmaceutical drug development and that is why we launched “The Diary of a Psychedelic Exec.”
If you are an investor or interested in psychedelic healing and what Psyence is up to, then please join us each week as we share the work of building a sustainable business that delivers shareholder value.

– Jody Aufrichtig, Co-founder and Executive Chairman, Psyence

We value your feedback – diary@psyence.com

Investor News

  • diary of psych exec | Psyence

The Diaries of a Psychedelic Exec : Episode 4

July 2, 2021|

In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

June 28, 2021|

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

  • GROUP_UPDATE_FEATURE

Psyence Group Corporate Update

May 27, 2021|

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.

  • How we grow Psilocybin Mushrooms | Psyence

How We Grow Our Psilocybin Mushrooms

May 7, 2021|

At Psyence we have sourced the world's best genetics, and coupled that with world leading expertise in the field of mycology, to produce the highest quality mushrooms. Our process is complex, but refined.

Investor News

  • diary of psych exec | Psyence

The Diaries of a Psychedelic Exec : Episode 4

In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

  • GROUP_UPDATE_FEATURE

Psyence Group Corporate Update

Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.

  • How we grow Psilocybin Mushrooms | Psyence

How We Grow Our Psilocybin Mushrooms

At Psyence we have sourced the world's best genetics, and coupled that with world leading expertise in the field of mycology, to produce the highest quality mushrooms. Our process is complex, but refined.

Why Psyence?

Focused on natural psychedelics

  • Psyence Production: Producing natural psilocybin at our federally licensed facility built to GMP standards
  • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences
  • Psyence Wellness: Uniquely positioned to serve the mental wellness economy valued at $121B market by the Global Wellness Institute
  • Psyence Experience: Innovators in guided-psychedelic experiences

Operational

  • In 2020, Psyence was granted a licence by the Kingdom of Lesotho to cultivate and export psilocybin mushrooms. Our state-of-the-art facility is already operational and is on track for BSI and GMP certification.

Extensive capital markets/business building experience

  • Experienced global executive team
  • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

  • Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
  • Our Scientific Advisory Board is led by Dr. Neil Maresky, vice president of Scientific affairs at Astra-Zeneca Canada

Extensive networks and partnerships

  • We are building partnerships with a network of institutions and companies including:
  • Government research centres
  • University hospitals and research centres
  • Regulatory stakeholders
  • Clinics, retreats and hospitality centres
  • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

  •  A mix of certified spores under cultivation
  • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
  • Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)

Functional mushroom brand

  • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP

Why Psyence?

Focused on natural psychedelics

  • Psyence Production: Producing natural psilocybin at our federally licensed facility built to GMP standards
  • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences
  • Psyence Wellness: Uniquely positioned to serve the mental wellness economy valued at $121B market by the Global Wellness Institute
  • Psyence Experience: Innovators in guided-psychedelic experiences

Operational

  • In 2020, Psyence was granted a licence by the Kingdom of Lesotho to cultivate and export psilocybin mushrooms. Our state-of-the-art facility is already operational and is on track for BSI and GMP certification.

Extensive capital markets/business building experience

  • Experienced global executive team
  • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

  • Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
  • Our Scientific Advisory Board is led by Dr. Neil Maresky, vice president of Scientific affairs at Astra-Zeneca Canada

Extensive networks and partnerships

  • We are building partnerships with a network of institutions and companies including:
  • Government research centres
  • University hospitals and research centres
  • Regulatory stakeholders
  • Clinics, retreats and hospitality centres
  • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

  •  A mix of certified spores under cultivation
  • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
  • Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)

Functional mushroom brand

  • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Investor Sign-Up

Please enter your details below to receive investor updates on Psyence Group


By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 200 Bay Street, Toronto, ON, M5J2J1, https://www.psyence.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP
Go to Top